9 results
10-Q
2024 Q1
GUTS
Fractyl Health Inc.
13 May 24
Quarterly report
4:06pm
approval;
commercial acceptance by patients, the medical community and third-party payors; and
our ability to compete with other therapies.
We do … , as such revenue is dependent upon our ability to establish, and then convince the medical community and third-party payors of, the clinical utility
10-K
2023 FY
GUTS
Fractyl Health Inc.
1 Apr 24
Annual report
7:15am
the clinical community and with prescribing physicians in particular.
Intellectual Property
Our ability to obtain and maintain intellectual property … ;
commercial acceptance by patients, the medical community and third-party payors; and
our ability to compete with other therapies.
We do not have complete
424B4
GUTS
Fractyl Health Inc.
2 Feb 24
Prospectus supplement with pricing info
4:18pm
community and third-party payors; and
our ability to compete with other therapies.
We do not have complete control over many of these factors … to establish, and then convince the medical community and third-party payors of, the clinical utility and economic benefits of our product candidates.
Third
S-1/A
GUTS
Fractyl Health Inc.
29 Jan 24
IPO registration (amended)
6:09am
, the medical community and third-party payors; and
our ability to compete with other therapies.
We do not have complete control over many of these factors … that are not yet approved for commercialization, as such revenue is dependent upon our ability to establish, and then convince the medical community
S-1/A
EX-10.16
GUTS
Fractyl Health Inc.
29 Jan 24
IPO registration (amended)
6:09am
to exercise of the Participant’s rights under the Plan. If the Participant is married and resides in a community property state, a designation of a person
S-1
k99kx 8e84
14 Dec 23
IPO registration
3:39pm
S-1
EX-4.1
iic0vler th
14 Dec 23
IPO registration
3:39pm
DRS/A
pjjisrzb
21 Sep 23
Draft registration statement (amended)
12:00am
DRS/A
fh8byg
22 Aug 23
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next